Search research articles
Contact Us
Filters
Showing results (11-20 of 106) with videos related to
Page
of 11
Sort By:
Cancers
|
March 10, 2022
Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
Thomas Cluzeau, Roberto M Lemoli, James McCloskey, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 23, 2003
Dendritic cell differentiation
Antonio Curti, Elisa Ferri, Simona Pandolfi, et al.
Expert Review of Anticancer Therapy
|
July 20, 2016
Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies
Michele Cea, Debora Soncini, Marco Gobbi, et al.
Haematologica
|
November 5, 2002
The therapeutic role of dendritic cells in cancer immunotherapy
Roberto M Lemoli, Antonio Curti, Miriam Fogli, et al.
Blood
|
November 22, 2008
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Antonio Curti, Sara Trabanelli, Valentina Salvestrini, et al.
Blood
|
July 13, 2012
The sixth sense: hematopoietic stem cells detect danger through purinergic signaling
Lara Rossi, Valentina Salvestrini, Davide Ferrari, et al.
Journal of Immunology Research
|
March 28, 2015
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response
Sara Trabanelli, Mariangela Lecciso, Valentina Salvestrini, et al.
Stem Cells and Development
|
December 25, 2012
Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages
Marilena Ciciarello, Roberta Zini, Lara Rossi, et al.
Oncotarget
|
December 2, 2016
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling
Dorian Forte, Valentina Salvestrini, Giulia Corradi, et al.
Frontiers in Oncology
|
March 6, 2024
Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy
Raffaele Palmieri, Atto Billio, Felicetto Ferrara, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 106) with videos related to
Sort By:
Page
of 11
Cancers
|
March 10, 2022
Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
Thomas Cluzeau, Roberto M Lemoli, James McCloskey, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 23, 2003
Dendritic cell differentiation
Antonio Curti, Elisa Ferri, Simona Pandolfi, et al.
Expert Review of Anticancer Therapy
|
July 20, 2016
Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies
Michele Cea, Debora Soncini, Marco Gobbi, et al.
Haematologica
|
November 5, 2002
The therapeutic role of dendritic cells in cancer immunotherapy
Roberto M Lemoli, Antonio Curti, Miriam Fogli, et al.
Blood
|
November 22, 2008
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Antonio Curti, Sara Trabanelli, Valentina Salvestrini, et al.
Blood
|
July 13, 2012
The sixth sense: hematopoietic stem cells detect danger through purinergic signaling
Lara Rossi, Valentina Salvestrini, Davide Ferrari, et al.
Journal of Immunology Research
|
March 28, 2015
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response
Sara Trabanelli, Mariangela Lecciso, Valentina Salvestrini, et al.
Stem Cells and Development
|
December 25, 2012
Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages
Marilena Ciciarello, Roberta Zini, Lara Rossi, et al.
Oncotarget
|
December 2, 2016
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling
Dorian Forte, Valentina Salvestrini, Giulia Corradi, et al.
Frontiers in Oncology
|
March 6, 2024
Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy
Raffaele Palmieri, Atto Billio, Felicetto Ferrara, et al.
Page
of 11